ArticleMolecular therapy : the journal of the American Society of Gene Therapy2017
Low-Dose Nitric Oxide as Targeted Anti-biofilm Adjunctive Therapy to Treat Chronic Pseudomonas aeruginosa Infection in Cystic Fibrosis.
Article in Molecular therapy : the journal of the American Society of Gene Therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 90 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
90 citing papers in PubMed, 1 synthesis or guideline pooled it, 201 citations in OpenAlex.
- Antibiotic adjuvant therapy for pulmonary infection in cystic fibrosis.The Cochrane database of systematic reviews · 2020Pooled it
- Staphylococcus aureus biofilms: molecular mechanisms, resistance determinants, and emerging therapeutic strategies.Molecular biology reports · 2026Review
- Nitric Oxide Donor Spermine-NONOate Elicits Endogenous Dispersal-Associated Transcriptional Responses to Promote Biofilm Dispersal inAntibiotics (Basel, Switzerland) · 2026Article
- Development of a light-induced gas phase nitric oxide generator and its use in killing biofilm bacteria in vitro and ex vivo.Journal of controlled release : official journal of the Controlled Release Society · 2026Article
- UnderstandingMicroorganisms · 2026Review
- Rapid means of biofilm disruption induce the newly released (NRel) phenotype of enhanced antibiotic sensitivity.Frontiers in microbiology · 2026Article
- Antimicrobial Resistance: The Answers.British journal of biomedical science · 2026Review
- Exploring Intervention Strategies for Microbial Biofilms in the Food Industry Based on a Biomolecular Mechanism Perspective: Recent Advances and Emerging Trends.Foods (Basel, Switzerland) · 2025Review
- Nitric oxide donor sodium nitroprusside serves as a source of iron supportingMicrobiology spectrum · 2025Article
- Efficacy of nitric oxide donors and EDTA againstBiofilm · 2025Article
- Establishment and characterization of persistentInfection and immunity · 2025Article
- Article
- The adaptability ofFrontiers in cellular and infection microbiology · 2025Review
- Harnessing the Power of Our Immune System: The Antimicrobial and Antibiofilm Properties of Nitric Oxide.Microorganisms · 2024Review
- Biofilm matrix: a multifaceted layer of biomolecules and a defensive barrier against antimicrobials.Archives of microbiology · 2024Review
- Biofilm Production and Its Implications in Pediatrics.Microorganisms · 2024Review
- Effects of elevated levels of intracellular nitric oxide on Pseudomonas aeruginosa biofilm in chronic skin wound and slow-killing infection models.International microbiology : the official journal of the Spanish Society for Microbiology · 2024Article
- The nitric oxide paradox: antimicrobial and inhibitor of antibiotic efficacy.Emerging topics in life sciences · 2024Article
- Polylactic acid-based dressing with oxygen generation and enzyme-like activity for accelerating both light-driven biofilm elimination and wound healing.Burns & trauma · 2024Article
- Mechanistic analysis of the photolytic decomposition of solid-state S-nitroso-N-acetylpenicillamine.Nitric oxide : biology and chemistry · 2024Article
30 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 12 institutions in 4 countries.
Funding
Abstract
Despite aggressive antibiotic therapy, bronchopulmonary colonization by Pseudomonas aeruginosa causes persistent morbidity and mortality in cystic fibrosis (CF). Chronic P. aeruginosa infection in the CF lung is associated with structured, antibiotic-tolerant bacterial aggregates known as biofilms. We have demonstrated the effects of non-bactericidal, low-dose nitric oxide (NO), a signaling molecule that induces biofilm dispersal, as a novel adjunctive therapy for P. aeruginosa biofilm infection in CF in an ex vivo model and a proof-of-concept double-blind clinical trial. Submicromolar NO concentrations alone caused disruption of biofilms within ex vivo CF sputum and a statistically significant decrease in ex vivo biofilm tolerance to tobramycin and tobramycin combined with ceftazidime. In the 12-patient randomized clinical trial, 10 ppm NO inhalation caused significant reduction in P. aeruginosa biofilm aggregates compared with placebo across 7 days of treatment. Our results suggest a benefit of using low-dose NO as adjunctive therapy to enhance the efficacy of antibiotics used to treat acute P. aeruginosa exacerbations in CF. Strategies to induce the disruption of biofilms have the potential to overcome biofilm-associated antibiotic tolerance in CF and other biofilm-related diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.